Base de dados : MEDLINE
Pesquisa : D02.455.426.100.080.100 [Categoria DeCS]
Referências encontradas : 413 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 42 ir para página                         

  1 / 413 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29341071
[Au] Autor:Bergman H; Soares-Weiser K
[Ad] Endereço:Cochrane Response, Cochrane, St Albans House, 57-59 Haymarket, London, UK, SW1Y 4QX.
[Ti] Título:Anticholinergic medication for antipsychotic-induced tardive dyskinesia.
[So] Source:Cochrane Database Syst Rev;1:CD000204, 2018 01 17.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Antipsychotic (neuroleptic) medication is used extensively to treat people with serious mental illnesses. However, it is associated with a wide range of adverse effects, including movement disorders. Because of this, many people treated with antipsychotic medication also receive anticholinergic drugs in order to reduce some of the associated movement side-effects. However, there is also a suggestion from animal experiments that the chronic administration of anticholinergics could cause tardive dyskinesia. OBJECTIVES: To determine whether the use or the withdrawal of anticholinergic drugs (benzhexol, benztropine, biperiden, orphenadrine, procyclidine, scopolamine, or trihexylphenidyl) are clinically effective for the treatment of people with both antipsychotic-induced tardive dyskinesia and schizophrenia or other chronic mental illnesses. SEARCH METHODS: We retrieved 712 references from searching the Cochrane Schizophrenia Group's Study-Based Register of Trials including the registries of clinical trials (16 July 2015 and 26 April 2017). We also inspected references of all identified studies for further trials and contacted authors of trials for additional information. SELECTION CRITERIA: We included reports identified in the search if they were controlled trials dealing with people with antipsychotic-induced tardive dyskinesia and schizophrenia or other chronic mental illness who had been randomly allocated to (a) anticholinergic medication versus placebo (or no intervention), (b) anticholinergic medication versus any other intervention for the treatment of tardive dyskinesia, or (c) withdrawal of anticholinergic medication versus continuation of anticholinergic medication. DATA COLLECTION AND ANALYSIS: We independently extracted data from included trials and we estimated risk ratios (RR) with 95% confidence intervals (CIs). We assumed that people who left early had no improvement. We assessed risk of bias and created a 'Summary of findings' table using GRADE. MAIN RESULTS: The previous version of this review included no trials. We identified two trials that could be included from the 2015 and 2017 searches. They randomised 30 in- and outpatients with schizophrenia in the USA and Germany. Overall, the risk of bias was unclear, mainly due to poor reporting: allocation concealment was not described; generation of the sequence was not explicit; studies were not clearly blinded; and outcome data were not fully reported.Findings were sparse. One study reported on the primary outcomes and found that significantly more participants allocated to procyclidine (anticholinergic) had not improved to a clinically important extent compared with those allocated to isocarboxazid (MAO-inhibitor) after 40 weeks' treatment (1 RCT, n = 20; RR 4.20, 95% CI 1.40 to 12.58; very low quality evidence); that there was no evidence of a difference in the incidence of any adverse effects (1 RCT, n = 20; RR 0.33, 95% CI 0.02 to 7.32; very low quality evidence); or acceptability of treatment (measured by participants leaving the study early) (1 RCT, n = 20; RR 0.33, 95% CI 0.02 to 7.32; very low quality evidence). The other trial compared anticholinergic withdrawal with anticholinergic continuation and found no evidence of a difference in the incidence of acceptability of treatment (measured by participants leaving the study early) (1 RCT, n = 10; RR 2.14, 95% CI 0.11 to 42.52; very low quality evidence).No trials reported on social confidence, social inclusion, social networks, or personalised quality of life - outcomes designated important to patients. No studies comparing either i. anticholinergics with placebo or no treatment, or ii. studies of anticholinergic withdrawal, were found that reported on the primary outcome 'no clinically important improvement in TD symptoms and adverse events'. AUTHORS' CONCLUSIONS: Based on currently available evidence, no confident statement can be made about the effectiveness of anticholinergics to treat people with antipsychotic-induced tardive dyskinesia. The same applies for the withdrawal of such medications. Whether the withdrawal of anticholinergics may benefit people with antipsychotic-induced TD should be evaluated in a parallel-group, placebo-controlled randomised trial, with adequate sample size and at least 6 weeks of follow-up.
[Mh] Termos MeSH primário: Antipsicóticos/efeitos adversos
Antagonistas Colinérgicos/uso terapêutico
Discinesia Induzida por Medicamentos/tratamento farmacológico
[Mh] Termos MeSH secundário: Biperideno/efeitos adversos
Biperideno/uso terapêutico
Antagonistas Colinérgicos/efeitos adversos
Discinesia Induzida por Medicamentos/etiologia
Seres Humanos
Isocarboxazida/efeitos adversos
Isocarboxazida/uso terapêutico
Prociclidina/efeitos adversos
Prociclidina/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Esquizofrenia/tratamento farmacológico
Suspensão de Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Cholinergic Antagonists); 0FRP6G56LD (Biperiden); 34237V843T (Isocarboxazid); C6QE1Q1TKR (Procyclidine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD000204.pub2


  2 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27552677
[Au] Autor:Ocaña-Zurita MC; Juárez-Rojop IE; Genis A; Tovilla-Zárate CA; González-Castro TB; Lilia López-Narváez M; de la O de la O ME; Nicolini H
[Ad] Endereço:a División Académica de Ciencias de la Salud , Universidad Juárez Autónoma de Tabasco , Villahermosa , Tabasco , México ;
[Ti] Título:Potential drug-drug interaction in Mexican patients with schizophrenia.
[So] Source:Int J Psychiatry Clin Pract;20(4):249-53, 2016 Nov.
[Is] ISSN:1471-1788
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was to observe potential drug-drug interactions in the medication of Mexican schizophrenic patients. METHODS: We performed a retrospective and cross-sectional study that was carried out in a psychiatric clinic. Only the prescriptions of patients with schizophrenia whose diagnoses were based on the DSM-IV instrument were included in this study. The Drug Interactions Checker software ( http://www.drugs.com/drug_interactions.html ) was used in this study to analyse potential drug-drug interactions. RESULTS: In total, 86 of 126 patients were at risk of potential drug-drug interactions. Haloperidol and biperiden was the most common drug pair of 232 pairs evaluated. In our study, 13.8% of drug-drug interaction showed a major level of severity, whereas in 83.2%, the interaction was moderate. Finally, central nervous system (CNS) depression and anticholinergic effect were the main possible effects of drug-drug interaction. CONCLUSIONS: Our results revealed a high number of patients with schizophrenia receiving two or more drugs. The potential drug-drug interactions observed in the Mexican population are consistent with the concomitant use of antipsychotics, benzodiazepines, and antidepressants prescribed in schizophrenia that could cause central nervous system (CNS) depression and anticholinergic effect. Drug-drug interaction must be considered when the patient with schizophrenia is medicated.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Incompatibilidade de Medicamentos
Interações Medicamentosas
Antagonistas Muscarínicos/uso terapêutico
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Antipsicóticos/efeitos adversos
Biperideno/efeitos adversos
Biperideno/uso terapêutico
Estudos Transversais
Feminino
Haloperidol/efeitos adversos
Haloperidol/uso terapêutico
Seres Humanos
Masculino
México/epidemiologia
Meia-Idade
Antagonistas Muscarínicos/efeitos adversos
Estudos Retrospectivos
Esquizofrenia/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Muscarinic Antagonists); 0FRP6G56LD (Biperiden); J6292F8L3D (Haloperidol)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170404
[Lr] Data última revisão:
170404
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160824
[St] Status:MEDLINE
[do] DOI:10.1080/13651501.2016.1213854


  3 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27186707
[Au] Autor:Yilmaz-Topa Ö; Tuygun N; Akça H; Polat E; Karacan CD
[Ad] Endereço:Department of Pediatrics, Dr. Sami Ulus Maternity and Children's Research and Training Hospital, Ankara, Turkey. osgee_87@hotmail.com.
[Ti] Título:Cetirizine and albendazole induced dystonia in a child.
[So] Source:Turk J Pediatr;57(4):407-408, 2015 Jul-Aug.
[Is] ISSN:0041-4301
[Cp] País de publicação:Turkey
[La] Idioma:eng
[Ab] Resumo:Drug-induced dystonic reactions are a common presentation to the Pediatric Emergency Department frequently with antiemetics, antidepressants, dopamineblocking agents and antipyschotics. We report a case of generalized form of dystonia after taking albendazole and cetirizine. There is only one case with albendazole induced and two cases with cetirizine induced dystonia in the literature.
[Mh] Termos MeSH primário: Albendazol/efeitos adversos
Anti-Helmínticos/efeitos adversos
Cetirizina/efeitos adversos
Distonia/induzido quimicamente
Antagonistas dos Receptores Histamínicos H1 não Sedativos/efeitos adversos
[Mh] Termos MeSH secundário: Biperideno/uso terapêutico
Pré-Escolar
Serviço Hospitalar de Emergência
Seres Humanos
Masculino
Antagonistas Muscarínicos/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Anthelmintics); 0 (Histamine H1 Antagonists, Non-Sedating); 0 (Muscarinic Antagonists); 0FRP6G56LD (Biperiden); F4216019LN (Albendazole); YO7261ME24 (Cetirizine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170216
[Lr] Data última revisão:
170216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160518
[St] Status:MEDLINE


  4 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26613233
[Au] Autor:Ayaydin H; Bozkurt H
[Ad] Endereço:Outpatient Clinic of Child and Adolescent Psychiatry, Edirne State Hospital, Edirne, Turkey. drhasan33@yahoo.com.
[Ti] Título:Spasmodic torticollis associated with sertraline in a child and an adolescent.
[So] Source:Turk J Pediatr;57(1):109-11, 2015 Jan-Feb.
[Is] ISSN:0041-4301
[Cp] País de publicação:Turkey
[La] Idioma:eng
[Ab] Resumo:Movement disorders or extrapyramidal symptoms (EPS) associated with selective serotonin reuptake inhibitors (SSRIs) have been reported. Although akathisia was found to be the most common EPS, and fluoxetine was implicated in the majority of the adverse reactions, there were also cases with EPS due to sertraline treatment. We present a child and an adolescent who developed torticollis (cervical dystonia) after using sertraline. To our knowledge, the child case is the first such report of sertraline-induced torticollis, and the adolescent case is the third in the literature.
[Mh] Termos MeSH primário: Biperideno/uso terapêutico
Antagonistas Muscarínicos/uso terapêutico
Inibidores da Captação de Serotonina/efeitos adversos
Sertralina/efeitos adversos
Torcicolo/induzido quimicamente
[Mh] Termos MeSH secundário: Adolescente
Criança
Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Muscarinic Antagonists); 0 (Serotonin Uptake Inhibitors); 0FRP6G56LD (Biperiden); QUC7NX6WMB (Sertraline)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:151128
[Lr] Data última revisão:
151128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151128
[St] Status:MEDLINE


  5 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26479221
[Au] Autor:Affaticati A; Gerra ML; Amerio A; Inglese M; Antonioni MC; Marchesi C
[Ad] Endereço:Department of Mental Health, Local Health Service, Parma, Italy Department of Neuroscience, Unit of Psychiatry, University of Parma, Parma, Italy marialidia.gerra@studenti.unipr.it Department of Neuroscience, Unit of Psychiatry, University of Parma, Parma, Italy and Mood Disorders Program, Tufts Medical Center, Boston, MA Department of Mental Health, Local Health Service, Parma, Italy Department of Mental Health, Local Health Service, Parma, Italy and Department of Neuroscience, Unit of Psychiatry, University of Parma, Parma, Italy.
[Ti] Título:The Controversial Case of Biperiden: From Prescription Drug to Drug of Abuse.
[So] Source:J Clin Psychopharmacol;35(6):749-50, 2015 Dec.
[Is] ISSN:1533-712X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Biperideno/efeitos adversos
Antagonistas Muscarínicos/efeitos adversos
Transtornos Relacionados ao Uso de Substâncias/fisiopatologia
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Muscarinic Antagonists); 0FRP6G56LD (Biperiden)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:151103
[Lr] Data última revisão:
151103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151020
[St] Status:MEDLINE
[do] DOI:10.1097/JCP.0000000000000421


  6 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25959965
[Au] Autor:Danielmeier C; Allen EA; Jocham G; Onur OA; Eichele T; Ullsperger M
[Ad] Endereço:Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Montessorilaan 3, 6525 HR Nijmegen, the Netherlands; Max Planck Institute for Neurological Research, Gleueler Strasse 50, 50931 Cologne, Germany; Department of Neuropsychology, Otto-von-Guericke-Universität, Universit
[Ti] Título:Acetylcholine mediates behavioral and neural post-error control.
[So] Source:Curr Biol;25(11):1461-8, 2015 Jun 01.
[Is] ISSN:1879-0445
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Humans often commit errors when they are distracted by irrelevant information and no longer focus on what is relevant to the task at hand. Adjustments following errors are essential for optimizing goal achievement. The posterior medial frontal cortex (pMFC), a key area for monitoring errors, has been shown to trigger such post-error adjustments by modulating activity in visual cortical areas. However, the mechanisms by which pMFC controls sensory cortices are unknown. We provide evidence for a mechanism based on pMFC-induced recruitment of cholinergic projections to task-relevant sensory areas. Using fMRI in healthy volunteers, we found that error-related pMFC activity predicted subsequent adjustments in task-relevant visual brain areas. In particular, following an error, activity increased in those visual cortical areas involved in processing task-relevant stimulus features, whereas activity decreased in areas representing irrelevant, distracting features. Following treatment with the muscarinic acetylcholine receptor antagonist biperiden, activity in visual areas was no longer under control of error-related pMFC activity. This was paralleled by abolished post-error behavioral adjustments under biperiden. Our results reveal a prominent role of acetylcholine in cognitive control that has not been recognized thus far. Regaining optimal performance after errors critically depends on top-down control of perception driven by the pMFC and mediated by acetylcholine. This may explain the lack of adaptivity in conditions with reduced availability of cortical acetylcholine, such as Alzheimer's disease.
[Mh] Termos MeSH primário: Acetilcolina/metabolismo
Comportamento/fisiologia
Cognição/fisiologia
Lobo Frontal/metabolismo
Córtex Visual/metabolismo
[Mh] Termos MeSH secundário: Adulto
Biperideno
Voluntários Saudáveis
Seres Humanos
Imagem por Ressonância Magnética
Masculino
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0FRP6G56LD (Biperiden); N9YNS0M02X (Acetylcholine)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:150603
[Lr] Data última revisão:
150603
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150512
[St] Status:MEDLINE


  7 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25839338
[Au] Autor:Ota T; Miura I; Kanno-Nozaki K; Hoshino H; Horikoshi S; Fujimori H; Kanno T; Mashiko H; Yabe H
[Ad] Endereço:From the *Department of Neuropsychiatry, Fukushima Medical University School of Medicine; and the †Fukushima Red Cross Hospital, Fukushima, Japan.
[Ti] Título:Effects of Shakuyaku-Kanzo-to on Extrapyramidal Symptoms During Antipsychotic Treatment: A Randomized, Open-Label Study.
[So] Source:J Clin Psychopharmacol;35(3):304-7, 2015 Jun.
[Is] ISSN:1533-712X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Extrapyramidal symptoms (EPS) are common adverse effects of antipsychotic treatment. This study examined the effects of the traditional Japanese herbal medicine (kampo) shakuyaku-kanzo-to on EPS during antipsychotic treatment. Twenty-two Japanese patients with psychiatric disorders who had developed EPS during antipsychotic treatment were randomly allocated to receive either shakuyaku-kanzo-to (7.5 g/d) or biperiden (3 mg/d) for 2 weeks. Extrapyramidal symptoms were evaluated using the Drug-Induced Extrapyramidal Symptom Scale (DIEPSS) and the Barnes Akathisia Rating Scale. Plasma levels of the monoamine metabolite homovanillic acid and serum prolactin levels were measured to investigate the mechanisms of action of shakuyaku-kanzo-to. Twenty of the 22 patients completed the study (10 patients in the shakuyaku-kanzo-to group and 10 patients in the biperiden group). There was a time effect on the Drug-Induced Extrapyramidal Symptom Scale total score (P < 0.01), suggesting that both shakuyaku-kanzo-to and biperiden decreased EPS. Notably, there was a time × drug interaction in dystonia, suggesting that shakuyaku-kanzo-to had a greater effect on dystonia compared with biperiden. No significant changes were observed in plasma homovanillic acid or serum prolactin levels after 2 weeks of treatment in either group. The effects of shakuyaku-kanzo-to on abnormal muscle tonus and dopamine D2 receptors may have contributed to improve EPS. These results suggest that shakuyaku-kanzo-to may be useful in decreasing EPS, especially dystonia, in patients undergoing treatment with antipsychotic agents.
[Mh] Termos MeSH primário: Antipsicóticos/efeitos adversos
Doenças dos Gânglios da Base/induzido quimicamente
Medicamentos de Ervas Chinesas/uso terapêutico
Medicina Kampo/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antiparkinsonianos/uso terapêutico
Doenças dos Gânglios da Base/tratamento farmacológico
Biperideno/uso terapêutico
Combinação de Medicamentos
Feminino
Ácido Homovanílico/sangue
Seres Humanos
Masculino
Meia-Idade
Prolactina/sangue
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antiparkinson Agents); 0 (Antipsychotic Agents); 0 (Drug Combinations); 0 (Drugs, Chinese Herbal); 0 (shakuyaku-kanzoh-toh); 0FRP6G56LD (Biperiden); 9002-62-4 (Prolactin); X77S6GMS36 (Homovanillic Acid)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:150430
[Lr] Data última revisão:
150430
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150404
[St] Status:MEDLINE
[do] DOI:10.1097/JCP.0000000000000312


  8 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25751433
[Au] Autor:Stocker L; Jellestad L; Jenewein J; Boettger S
[Ad] Endereço:Department of Psychiatry and Psychotherapy, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland, Lea.Stocker@usz.ch.
[Ti] Título:Challenges in the management of delirium: a case of augmentation with donepezil following inadequate response and adverse effects with risperidone.
[So] Source:Psychiatr Danub;27(1):64-6, 2015 Mar.
[Is] ISSN:0353-5053
[Cp] País de publicação:Croatia
[La] Idioma:eng
[Mh] Termos MeSH primário: Síndrome Anticolinérgica
Biperideno/efeitos adversos
Delírio
Indanos/administração & dosagem
Rigidez Muscular
Fisostigmina/administração & dosagem
Piperidinas/administração & dosagem
Risperidona/efeitos adversos
[Mh] Termos MeSH secundário: Síndrome Anticolinérgica/tratamento farmacológico
Síndrome Anticolinérgica/etiologia
Antiparkinsonianos/administração & dosagem
Antiparkinsonianos/efeitos adversos
Antipsicóticos/administração & dosagem
Antipsicóticos/efeitos adversos
Biperideno/administração & dosagem
Queimaduras/complicações
Queimaduras/metabolismo
Queimaduras/fisiopatologia
Queimaduras/terapia
Inibidores da Colinesterase/administração & dosagem
Delírio/diagnóstico
Delírio/tratamento farmacológico
Delírio/etiologia
Delírio/psicologia
Diagnóstico Diferencial
Vias de Administração de Medicamentos
Sinergismo Farmacológico
Seres Humanos
Masculino
Meia-Idade
Rigidez Muscular/induzido quimicamente
Rigidez Muscular/tratamento farmacológico
Risperidona/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiparkinson Agents); 0 (Antipsychotic Agents); 0 (Cholinesterase Inhibitors); 0 (Indans); 0 (Piperidines); 0FRP6G56LD (Biperiden); 8SSC91326P (donepezil); 9U1VM840SP (Physostigmine); L6UH7ZF8HC (Risperidone)
[Em] Mês de entrada:1506
[Cu] Atualização por classe:150310
[Lr] Data última revisão:
150310
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150310
[St] Status:MEDLINE


  9 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25466702
[Au] Autor:Sambeth A; Riedel WJ; Klinkenberg I; Kähkönen S; Blokland A
[Ad] Endereço:Faculty of Psychology and Neuroscience, Department of Neuropsychology and Psychopharmacology, Maastricht University, Universiteitssingel 40, 6229 ER, Maastricht, The Netherlands, anke.sambeth@maastrichtuniversity.nl.
[Ti] Título:Biperiden selectively induces memory impairment in healthy volunteers: no interaction with citalopram.
[So] Source:Psychopharmacology (Berl);232(11):1887-97, 2015 Jun.
[Is] ISSN:1432-2072
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Traditionally, the non-selective muscarinic antagonist scopolamine has been used to induce episodic memory impairments as found in Alzheimer's disease (AD). However, it also impairs attention and induces drowsiness. Muscarinic antagonists more selective for the M1 receptor might, therefore, be preferred. OBJECTIVES: We examined the effects of the M1 antagonist biperiden on cognitive functions in order to test the specificity of this drug on memory performance. Additionally, we assessed whether the selective serotonin re-uptake inhibitor citalopram can reverse a possible biperiden-induced impairment. METHODS: The study was conducted according to a double-blind, placebo-controlled, four-way cross-over design. Sixteen volunteers received biperiden (2 mg), citalopram (20 mg), a combination of the two, or a placebo in counterbalanced order with a washout of at least 4 days. Cognitive tests (verbal memory, continuous recognition memory, spatial memory, choice reaction) were performed 4 and 1 h after treatment with citalopram and biperiden, respectively. RESULTS: Biperiden impaired memory performance in the verbal learning task, the continuous recognition memory test, and the spatial memory task. Effects on attention and side effects, as measured using the choice reaction time test and questionnaires respectively, could be neglected. Citalopram did not affect any of the memory or attention measures taken. Most importantly, citalopram was also unable to reverse the biperiden-induced memory impairments. CONCLUSIONS: Our results, thus, show that the M1 antagonist biperiden may serve as a translational model to induce episodic memory deficits as seen in AD. However, the interactive influence of acetylcholine and serotonin on memory could not be confirmed.
[Mh] Termos MeSH primário: Biperideno/toxicidade
Citalopram/farmacologia
Transtornos da Memória/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Doença de Alzheimer/induzido quimicamente
Doença de Alzheimer/psicologia
Atenção/efeitos dos fármacos
Estudos Cross-Over
Método Duplo-Cego
Feminino
Voluntários Saudáveis
Seres Humanos
Masculino
Transtornos da Memória/diagnóstico
Rememoração Mental/efeitos dos fármacos
Testes Neuropsicológicos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0DHU5B8D6V (Citalopram); 0FRP6G56LD (Biperiden)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141204
[St] Status:MEDLINE
[do] DOI:10.1007/s00213-014-3822-9


  10 / 413 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25373869
[Au] Autor:Veselinovic T; Vernaleken I; Janouschek H; Kellermann T; Paulzen M; Cumming P; Gründer G
[Ad] Endereço:Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany, tveselinovic@ukaachen.de.
[Ti] Título:Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers.
[So] Source:Psychopharmacology (Berl);232(9):1607-17, 2015 May.
[Is] ISSN:1432-2072
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Many aspects of the neurobiology of schizophrenia, especially the physiological basis of the negative symptoms and associated cognitive deficits, remain inadequately understood. Tandon and Greden (1989) postulated a central role of dopaminergic/cholinergic imbalance in schizophrenia. OBJECTIVE/METHODS: In light of this hypothesis, we elected to investigate the effects of anticholinergic challenge on psychopathology, cognition and attention in 12 unmedicated patients with schizophrenia and 12 healthy controls. The first examination occurred before any pharmacological intervention; the second examination was carried out immediately following an intravenous infusion of 5 mg biperiden, a centrally acting antimuscarinergic agent. RESULTS: The biperiden challenge provoked a considerable increase in PANSS scores in both groups which was significantly more pronounced in patients (repeated measures analysis of variance (ANOVA) (rmANOVA): F(df) = 6.4(1,22); p = 0.019). The increase in the PANSS scores showed a significant negative correlation with age in patients. Biperiden caused considerable cognitive impairments in both groups. A significant group difference (rmANOVA) could be observed for TMT-B (F(df) = 11.29(1,22); p = 0.003). CONCLUSIONS: The anticholinergic intervention caused more pronounced psychopathological and cognitive deteriorating effects in patients suffering from schizophrenia than in healthy volunteers. This could be related to the disrupted cholinergic transmission in schizophrenia. Our findings speak on behalf of the need of a more restrictive use of anticholinergics in psychiatric patients. The age-related attenuation of PANSS score increases in patients could be related to the age-dependent changes in dopamine dynamics and also to the age-associated decline of the availability of muscarinic receptors. Our results emphasise the need for further investigation of cholinergic disturbances in schizophrenia.
[Mh] Termos MeSH primário: Atenção/efeitos dos fármacos
Biperideno/farmacologia
Cognição/efeitos dos fármacos
Antagonistas Muscarínicos/farmacologia
Psicologia do Esquizofrênico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Transtornos Cognitivos/etiologia
Feminino
Voluntários Saudáveis
Seres Humanos
Masculino
Testes Neuropsicológicos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Muscarinic Antagonists); 0FRP6G56LD (Biperiden)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141107
[St] Status:MEDLINE
[do] DOI:10.1007/s00213-014-3794-9



página 1 de 42 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde